The FDA-approved BRAF inhibitor vemurafenib achieves outstanding clinical response rates in patients with melanoma, but early resistance is common. Understanding the pathologic mechanisms of drug resistance and identification of effective therapeutic alternatives are key scientific challenges in the melanoma setting. Using proteomic techniques including shotgun analysis and 2D-gel electrophoresis, we identified a comprehensive signature of the vemurafenib-resistant M24met in comparison to the vemurafenib-sensitive A375 melanoma cell line. The resistant cells were characterized by loss of differentiation, induction of transformation, enhanced expression of the lysosomal compartment, increased potential for metastasis, migration, adherence and Ca2+ ion binding, enhanced expression of MAPK pathway and extracellular matrix proteins, and epithelial-mesenchymal transformation. The main features were verified by shotgun analysis with QEXACTIVE orbitrap MS, electron microscopy, lysosomal staining, western blotting, and adherence assay in a VM-1 melanoma cell line with acquired vemurafenib resistance. Based on the resistance profile, we were able to successfully predict that a novel resveratrol-derived COX-2 inhibitor, M8, would be active against the vemurafenib-resistant but not the vemurafenib-sensitive melanoma cells.
1.Introduction
During the last 10 years the incidence of melanoma has increased more rapidly than that of any other cancer type. Up to one-fifth of patients develop metastatic disease, which is associated with poor prognosis and a median survival of 7.5 months. Dacarbazine, the mainstay of treatment for metastatic melanoma over the last 30 years, achieves response rates of 22% but does not improve survival (1) . After decades of failed attempts to improve treatment outcomes, two new drugs, ipilimumab and vemurafenib (PLX4032), were shown in randomized phase III clinical trials to significantly enhance overall survival (2, 3) .
Vemurafenib, a novel small-molecule BRAF inhibitor, was approved by the FDA in August 2011 for the treatment of metastatic or inoperable melanoma harboring a BRAF V600E mutation (4) .
Mutational activation of BRAF V600E is one of the most prevalent genetic alterations in human melanoma (50% of all melanomas). Clinical responses, including complete
remissions, were achieved with vemurafenib in 80% of patients with BRAF V600E-mutated melanomas. However, acquired drug resistance frequently emerged after 2-18 months (5).
Despite intensive efforts, an understanding of resistance to BRAF inhibitors has yet to be achieved. The plasticity and heterogeneity of melanoma cells could potentially allow multiple adaptive mechanisms (e.g. epithelial-mesenchymal transition [EMT] , and differences in proliferation, motility or stem cell-like characteristics) (6) . Thus, it is unlikely that a single biomarker would serve to indicate drug resistance. bioinformatics can support the understanding of drug resistance mechanisms, with the potential to guide individually tailored therapy (7) .
In the present study, we sought to extend our earlier work (7), using high-throughput techniques such as shotgun analysis and 2D-gel electrophoresis to compare the features of vemurafenib-sensitive and -resistant melanoma cell lines and identify a comprehensive signature of vemurafenib resistance. Based on these findings, we aimed to explore whether proteome analysis could be used to predict sensitivity to a rationally chosen agent, based on its mechanism of action.
Material and Methods

Cell line and Chemicals
The A375 melanoma cell line (American Type Culture Collection) harbors a mutation in BRAFV600E, while the metastatic M24met line harbors a mutation in NRAS, a deletion in p16 and amplification in EGFR. Melanoma cells expressing the BRAF mutation are reported to be vemurafenib-sensitive, while resistance may be associated with NRAS mutation or activation (8, 9) . The M24met cell line was previously found to be resistant to cisplatin, while the A375 was sensitive (7) . M24met and A375 melanoma cells were described previously (7, 10) and where obtained in 2005.
M24met cells (kindly provided by Dr. R.A. Reisfeld, Department of Immunology, Scripps
Research Institute, La Jolla, CA; were grown in RPMI 1640 supplemented with 10% fetal bovine serum, 2mM glutamine and 50 µg/ml gentamycin sulfate. A375 were grown in D-MEM tissue culture medium supplemented with 10% fetal bovine serum, 2mM glutamine and 50µg/ml gentamycin sulphate as described previously.
We studied these two cell lines to gain an initial understanding of vemurafenib sensitivity and resistance and subsequently attempted to verify these changes in an established melanoma model with acquired vemurafenib resistance.
For this purpose we used a vemurafenib-sensitive cell line VM-1, which harbours the mutation BRAF V600E (11) . VM-1 cells have been established at the Institute of Cancer
Research from a lymph node metastasis (primary tumor: superficial spreading melanoma) from a female patient in 1978 and were obtained by us in 2012. The cell lines were authenticated at the Institute of Cancer Research in all cases by array comparative genomic hybridization (Agilent; 44k human whole genome DNA arrays) as published previously (12) and STR fingerprinting during this study in June 2014.
We generated a series of melanoma cell lines with increasing vemurafenib resistance, by exposing a vemurafenib-sensitive cell line VM-1 (V0) to increasing concentrations of the drug: 0.5, 1 and 10µM. The resultant cell lines were termed V0.5, V1, and V10, respectively: V0 is the sensitive parent cell line.
3,3′,4,4′,5,5′-hexahydroxystilbene (M8) was provided by the Department of Pharmaceutical Chemistry, University of Vienna, Austria, frozen as 50mM or 10mM stock solutions in DMSO (Sigma-Aldrich) and diluted in RPMI as required (13) . Vemurafenib, diluted in DMSO, was purchased from Fa.Eubio.
Cell proliferation assay
The CellTiter 96 ® AQ ueous Non-Radioactive Cell Proliferation Assay (Promega) was used according to manufacturer guidelines as described previously (10) . In brief, cells are plated in 96 well plates (1500 cells/well). After 24h, increasing concentrations of vemurafenib, M8 or a solvent control (DMSO alone) were added. After 48h, proliferation is measured at 490nm
with an ELISA plate reader.
FACS analysis
FACS analysis of A375 and M24met melanoma cells was performed as described previously (14) .
Lysosomal staining
Lysosomal staining of vemurafenib-sensitive and -resistant cells was performed as described previously (7) using Lysotracker Red DND-99 (Molecular Probes; L7528). Cells were seeded on coverslips, treated with DMSO or vemurafenib for 48h and incubated with Lysotracker
Red for 1h at 37°C. Images were captured by a Zeiss confocal microscope.
Scanning electron microscopy (SEM)
SEM with V0, V0.5, V1 and V10 was performed as described previously (15) . Critical point drying was applied. The SEM images were taken at a magnification between 500 and 6000 using a Leo DSM 982 field emission scanning electron microscope at 4 kV.
CytoSelect™ 48-Well Cell Adhesion Assay (ECM Array, Colorimetric Format)
The ECM Array was performed as described previously (7). Vemurafenib-resistant andsensitive cells were allowed to attach to ECM-coated well plates for 1 hour at 100.000 cells/well. Unbound cells were washed away and the adherent cells stained and quantified calorimetrically.
Immunohistochemical staining of the primary melanoma cells
M24met and A375 melanoma cells were grown on tissue culture chamber slides (Nalge Nunc, Naperville, IL, US) and fixed in 4% formaldehyde then stained with the primary antibodies HMB45, Melan A, S100 (Dako, Corporation, Carpinteria, CA, USA), Nestin (IBL, Fujioka, Japan) and p75NTR (Sigma, St Louis, MO, USA), as described previously (13).
Western Blot
Cells (A375, M24met and vemurafenib-sensitive and -resistant melanoma cells) were frozen in liquid nitrogen and lysed with lysis buffer containing phosphatase and protease inhibitors as described previously (10, 16) . Membranes were incubated with the following primary antibodies: monoclonal mouse anti-human Vimentin Clone V9 (Dako), N-cadherin or Ecadherin (Cell Signaling).
Zymography Assay
Zymography Assay was performed as described previously (10) . The supernatant of V0, V0.5, V1 and V10 was collected. The SDS gel contained gelatine (1mg/ml), was stained in Coomassie solution for 30 minutes and stripped with an isopropanol-acetic acid solution (BioTeZ Berlin-Buch GmbH, Berlin, Germany).
Proteome analysis
Proteome analysis was performed as described previously (7, 10).
Subcellular fractionation and 1D PAGE
All fractionation steps were performed on ice. To obtain the cytoplasmic fraction, A375, M24met, V0 and V1 cells were lysed in isotonic lysis buffer (10 mM HEPES/NaOH, pH 7.4, 0.25 M sucrose, 10 mM NaCl, 3 mM MgCl2, 0.5% Triton X-100) supplemented with protease inhibitors (pepstatin, leupeptin and aprotinin, each at 1 μg/ml; 1 mM PMSF) and mechanical shear stress. In addition we performed nuclear fractionation of V0 and V1 cells.
By centrifugation at 2300xg and 4°C for 5min the cytoplasmic proteins were separated from the nuclei and precipitated overnight with ice-cold ethanol at -20°C. After precipitation, proteins were dissolved in sample buffer (7.5 M urea, 1.5 M thiourea, 4% CHAPS, 0.05% SDS, 100 mM DTT); the determination of protein concentration was carried out using a Bradford assay (Bio-Rad-Laboratories, Germany). For gaining nuclear proteins, pellets were swelled up for 10min in extraction buffer (500 mM NaCl) and 1:10 diluted with NP-40 buffer for another 15min. To obtain the nuclear fraction, centrifugation at 2300g and 4°C for 5min was performed. The extracted proteins were then precipitated overnight with ice-cold ethanol at -20°C. After precipitation, all samples were dissolved in sample buffer (7.5 M urea, 1.5 M thiourea, 4% CHAPS, 0.05% SDS, 100 mM DDT) and the protein concentrations were determined by means of Bradford assay (Bio-Rad-Laboratories, Germany). MS-sample preparation 20µg of each sample was loaded on SDS-PAGE. The different protein fractions were loaded separately on 12% polyacrylamid gels. Electrophoresis was performed until complete separation of a pre-stained molecular marker (Dual Color, Biorad, Hercules, CA).
Proteins in the gels were stained by a MS-compatible silver staining. After fixation with 50% methanol/10% acetic acid, the gels were washed by bi-distilled water and the proteins inside the gel were sensitized with 0.02% Na2S2O3. Gels were then stained with ice-cold 0.1% AgNO3 for 10min, rinsed by bi-distilled water and subsequently developed with 3% Na2CO3/0.05% formaldehyde. Afterwards, each protein band was cut into 8 slices and destained. Upon reduction with DTT (dithiothreitol) and alkylation with IAA (iodoacetamide), the proteins were digested enzymatically overnight at 37°C using trypsin (Roche Diagnostics, Germany). The peptides were eluted, dried and stored at -20°C until LC-MS analysis.
2D-gel electrophoresis
2D-gel electrophoresis was performed as described previously (17) . The cytosolic protein extracts of A375 and M24met cells used as well for shotgun analysis were loaded by passive rehydration of IPG strips pH 5-8, 17cm at room temperature followed by isoelectric focusing (IEF) which was performed in a stepwise fashion (1h 0-500V linear; 5h 500V; 5h 500-3500V linear; 12h 3500V). Equilibration was performed with 100mM DTT and 2.5% iodacetamide according to manufacturer instructions (Bio-Rad Hercules, CA). For SDS-PAGE, the IPG strips were placed on top of 1.5mm 12% polyacrylamide slab gels and overlaid with 0.5% low-melting agarose. Gels were stained with a 400nM solution of Ruthenium II tris (bathophenanthroline disulfonate) (RuBPS) (18) and scanned with the FluorImager 595 (Amersham Biosciences, Amersham, UK) at a resolution of 100μm. The gels were dried and storage phosphor screens (Molecular Dynamics) were exposed at room temperature for 24h.
Screens were subsequently scanned using the Phosphorimager SI (Molecular Dynamics) at a resolution of 100μm. Gels were adjusted to a reference gel with the TT900 S2S software (version 2006.0.2389, Nonlinear dynamics, Carlsbad, CA) and evaluated with the Progenesis software PG200 (version 2006, Nonlinear) using the "same spot" algorithm. Spot assignment, background correction, normalization and statistical calculations (analysis of variance, ANOVA) were performed using this software package. For protein identification, peptides were isolated as described above and separated by nanoflow liquid chromatography (1100 Series LC system, Agilent) as described below.
Shotgun analysis using Agilent nanoflow LC
Peptides of the cytoplasmic fraction of A375 and M24met were separated by nano-flow LC using the HPLC-Chip technology from Agilent, equipped with a 40 nl Zorbax 300SB-C18 trapping column and a 75 µm x 150 mm Zorbax 300SB-C18 separation column. For peptide elution we applied a gradient from 0.2% formic acid and 3% ACN to 0.2% formic acid and 40% ACN over 60 minutes at a flow rate of 400nL/min. were searched within a m/z range from 400 to 1400, fragmentation was triggered for the four highest peptide candidates, allowing for three independent fragmentations and using a dynamic exclusion list lasting for 1min. Precursor mass deviation was limited to a maximum of 1.5 Da, the product mass tolerance to maximal 0.7 Da and the minimum matched peak intensity (%SPI) to 70%. A peptide was included in the result files when it's SpectrumMill score was above. Peptides scoring between 9 and 13 were only included if precursor m/z value, retention time and MS2 pattern matched to a reference spectrum scoring above.
Concerning protein inference, we chose the smallest number of proteins necessary to explain all observed peptides as described for ProteinProphet. Furthermore, only proteins identified with at least two distinct peptides were included. Selection of protein identification was also based on robustness. Only peptide identifications reproduced in at least two different samples were included. The false discovery rate was determined by searching against the corresponding reversed database. Our filtering steps led to peptide identifications with consistently less than 1% apparent identifications when searching against the reversed database compared to the search against the true database, demonstrating high data accuracy.
Identification details for each protein including all identified peptides, sequence coverage, peptide scores and MS2 spectra are fully accessible via the PRIDE database (http://www.ebi.ac.uk/pride/).
Shotgun analysis using QEXACTIVE orbitrap MS
Peptides of the cytoplasmic and nuclear fraction V0 and V1 were separated using nanoflow UHPLC (Dionex Ultimate 3000) with a 50cm x 75µm 2µm particle size Pepmap100 column (Thermo Fisher Scientific, Austria) and a flow rate of 300 nl/min, using 100% mobile phase Annotation enrichment analysis was performed based on gene ontology cellular compartment, molecular function and biological process terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways according to Geiger et al.(22) .
Results
Interaction of vemurafenib with the kinase domain of BRAF (V600E).
Vemurafenib is a small-molecule BRAF inhibitor active against V600E-mutated melanoma.
Three-dimensional modeling of BRAF bound by vemurafenib and non-liganded BRAF ( Figure 1) shows that vemurafenib may hamper E600 from forming a salt bridge with K507.
Characterization of A375 and M24met
The cisplatin-resistant M24met cell line was found to also be resistant to vemurafenib, while the cisplatin-sensitive A375 was also sensitive to vemurafenib (Supplementary Table   1 ).
Immunohistochemistry and fluorescence-activated cell sorting (FACS) analysis revealed that A375 cells exhibited a small rounded cell shape, whereas M24met were characterized by sprouted cells with a larger cytoplasmic compartment. These cells formed tubes, a characteristic feature of endothelial cells ( Figure S1A ). M24met and A375 expressed the melanoma marker proteins S100, p75 NTR and nestin, but were negative for the fibroblast cell marker protein CD90, the endothelial marker proteins CD31 and CD34 and the leukocyte marker protein CD45 (Figure S1c-d) . A375 cells also showed a higher proliferation rate than M24met.
Protein expression pattern
2D gel electrophoresis (2D-PAGE) of the cytoplasmic fraction of A375 and M24met was then performed. Of 750 spots individually cut from the gel, digested and analyzed by nano-LC 
MS/MS, a total of 588 distinct proteins were successfully identified. In case of 58 spots no successful identification was achieved, 86 proteins were identified in two different spots and 18 proteins were identified in three different spots. 354 of the 588 identified proteins were common or ubiquitously expressed proteins that can be found in a great number of different cell types (23) . Table 2 ).
These observations led us to the hypothesis that the upregulated proteins which are the main target of the drug predict the resistance of the melanoma cells, while cells expressing less of these proteins would be sensitive.
Vemurafenib resistance and M8 sensitivity pattern
Recently, we characterized 3,3`,4,4`,5,5`-hexahydroxystilbene (M8), a novel hydroxyl derivative of resveratrol and potent antioxidant, to have superior anti-tumor activities against melanoma in vitro and in vivo. M8 was found to act by inhibiting cell proliferation, activating p53 and inducing cell cycle arrest and DNA damage (13) . Since A375 cells overexpress all these features in which M8 interferes, we hypothesized that A375 might be resistant, and Vemurafenib-resistant cells sensitive, to M8. Proliferation assay confirmed that indeed, this was the case (Supplementary Table 1 ).
The vemurafenib-resistant cells V0.5, V1, and V10 were more sensitive to M8 than the sensitive parent cell line V0 (Supplementary Table 1 Lysosomal staining revealed that the vemurafenib-sensitive V0 cells contained fewer lysosomes and these appeared rather small and granular, whereas in the resistant cell lines more lysosomes were present and these appeared as larger spherules. In V10 the lysosomes appeared to be excreted and shed by the cells (Figure 3c ).
In order to verify our observed signature in A375 and M24met melanoma cell lines, we performed shotgun analysis with the well-defined acquired resistance model V0 and V1.
Shotgun analysis of the cytoplasmic and nuclear fractions of V0 and V1 was done using QEXACTIVE orbitrap MS. In the cytoplasmic fraction we identified 5069/48261 (number of proteins/peptides) in V0 and 4078/34904 in V1. In the nuclear fraction we identified 4484/ 41824 in V0 and 4029/ 36322 in V1. Using MaxQuant analysis we generated heatmaps of the cytoplasmic and nuclear fractions of V0 and V1. Unsupervised hierarchical clustering of Zscored protein abundances of the cytoplasmic fraction yielded comparable results to the nuclear fraction. The main differences in the cytoplasmic fraction were found in clusters 3 and 4 ( Figure 4 ) whereas in the nuclear fraction the main differences were in clusters 1 and 5 ( Figure S2 ).
The groups significantly upregulated in V1 were cell adhesion; the lysosomal compartment; cell adhesion molecules; glycosaminoglycan degradation; phagosomes; calcium ion binding; regulation of peptidyl-serine phosphorylation; hydrolase activity; G-protein coupled receptor protein signaling pathway; cell migration; locomotion; chemotaxis; positive regulation of MAPKK cascade, and glycosphingolipid metabolic process. Some of these groups were also found to be upregulated in the nuclear fraction of V1 in addition to e.g. antigen processing and presentation. In comparison, the significant upregulated groups in V0 were different metabolic processes; translational processes; RNA transport and binding; cell cycle processes; NADH dehydrogenase, oxireductase and mitochondrial activity; DNA damage and repair, and signal transduction by p53 (Figure 4 and S2) . Interestingly, the main differences were also detectable by comparing the shotgun data for A375 (comparable to V0) versus M24met (comparable to V1), as presented in Figure 2 and also reported recently (7). The main differences are summarized in Table 1 .
Expression of EMT markers
Since the observed morphological changes in resistant cells might be due to EMT and EMT markers such as vimentin and fibronectin, shown to be enhanced in the M24met cells ( integrin alpha V, and ILK-1, whereas A375 exhibited higher expression of the epithelial marker desmoplakin, which is associated with cell adherence (Figure 5a, 5b) . The most prominent difference was seen in the vimentin expression and this was verified by western blot analysis (Figure 5a ).
Since EMT is associated with induction of resistance and metastasis (24-26), we performed western blot analysis of key EMT markers in the vemurafenib-sensitive andresistant cells. Loss of E-cadherin accompanied by a gain in N-cadherin is considered to be a fundamental event in EMT (25) . An E-cadherin/N-cadherin switch was evident in the vemurafenib-resistant cell line, with a total loss of E-cadherin in V0.5 and V1, and low expression of E-cadherin in V10 (Figure 5c ). In the proteome data we identified only E cadherin in V0 whereas vimentin and further EMT markers such as integrin alpha and beta V were identified with more peptides in V1 (Figure 5c ).
EMT is also associated with a higher expression of matrix metalloproteinases (Figure 5d ).
Adherence to ECM proteins
We previously demonstrated that M24met exhibit a higher capability for cell adherence in contrast to A375 (7). Therefore we hypothesized that the vemurafenib-resistant cells undergoing EMT have an increased ability to interact with ECM proteins.
A cell adhesion assay (7) confirmed that all vemurafenib-resistant cells adhered with distinctly higher potency to Collagen I. The V0.5 cells adhered to all coated ECM proteins.
The highest adherence to collagen IV and laminin I was seen in V0.5, followed by V1 and then V10, whereas the vemurafenib-sensitive V0 cells exhibited no, or marginally measurable, adherence (Figure 6a, 6b) .
Cell Similarity analysis
We subsequently compared the shotgun data of the cytoplasmic fraction of A375 and M24met to those of 226 different cell types and cell states represented in our database, using the Cell Similarity Tool designed by our group (7). A375 was found to have the greatest cell similarity (58%) to melanocytes, whereas M24met exhibited the greatest cell similarity to fibroblasts of multiple myeloma (77%) and endothelial cells stimulated with vascular endothelial growth factor (VEGF) (76%) (Figure 6c ).
We identified more peptides corresponding to proteins specific for melanocytes in A375 (n=24) compared to M24met (n=3), whereas in M24met there were more peptides specific for endothelial cells (n=14) compared to A375 (n=3) (Figure 6d ).
We identified 995 proteins that were found only in V0 or upregulated 3-fold versus V1; 741 were part of the GPDE, with the highest cell similarity to A375. In contrast, we found 160 
4.Discussion
Vemurafenib resistance is a key problem for melanoma treatment and an understanding of the underlying mechanisms may help to develop not only predictive and pharmacodynamic biomarkers, but also individualized targeted therapeutic interventions.
Recently, we used proteomics to define the characteristics of cisplatin resistance in melanoma cells (7) . Using proteomic methods we have now extended this profile to further features. The BRAF-mutated A375 are sensitive to both vemurafenib and cisplatin, whereas the NRAS-mutated M24met are resistant. This pattern of sensitivity can be correlated to a distinct morphologic phenotype, genetic background, proteome profile and cell biology. In addition we performed proteome analysis of a melanoma model with acquired vemurafenib resistance.
As summarized in Table 1 
enhanced expression of proteins involved in the MAPK pathway, metastasis and cell migration, adhesion and ECM proteins, and fewer proteins involved in DNA repair, cell cycle, p53 pathway and redox homeostasis. Notably, transition from an epidermal to a mesenchymal phenotype was seen, with upregulation of vimentin and fibronectin, a switch from E-cadherin to N-cadherin, higher activity of MMP2 and an enhanced cell adherence function and a melanocytic-endothelial switch.
We predicted that a drug targeting the downregulated proteins might be able to overcome resistance and indeed were able to show that the vemurafenib-resistant cells were highly sensitive to the resveratrol derivative M8. The workflow of the whole study is summarized in Figure S4 . Downregulation of the DNA repair enzyme DNA-dependent protein (DNA-PK) has been linked to a highly aggressive tumor behaviour (27) . Activation of the DNA-PKC S results in p53 phosphorylation (28, 29) . This observation is in line with our recent findings that M8 induces the phosphorylation of p53, proteins involved in the mismatch repair machinery (MSH6, MSH2, MLH1) and a robust tail moment in a comet assay (13) . The enhancement of the lysosomal compartment and phagosomal processes might be also due to autophagy, which is a multistep process that involves the sequestration of organelles and proteins in autophagic vesicles and subsequent lysosome-dependent degradation (36) . Druginduced autophagy has emerged as a common pathway of resistance to a number of kinase inhibitors, instead less is known about the link between MAPK signaling and autophagy.
Very recently, it was demonstrated that BRAFi induces cytoprotective autophagy through activation of an ER stress response and that targeting the ER stress-autophagy pathway might overcome BRAFi resistance in melanoma (36) .
Early EMT was shown to be associated with degradation of E-cadherin in the lysosomal compartment and EMT was prevented by lysosomal inhibitors (37) . Therefore, vemurafenib resistance might be characterized by lysosomal degradation of E-cadherin and subsequent EMT. EMT is known to include enhanced cell migration and metastasis, generation of cells with stem cell-like characteristics and increased resistance to chemotherapy and apoptosis (24) (25) (26) .
E-cadherin loss is a fundamental event, leading to a loss of close cell-cell contact, increased invasiveness and a typical change in morphology (24, 25) and was demonstrated in the vemurafenib-resistant cells. Downregulation or loss of E-cadherin was demonstrated to be sufficient to determine resistance (38, 39) and has been linked to decreased patient survival (40) . In parallel to the E-cadherin loss, EMT is involved with induction of the mesenchymal markers N-cadherin, reorganization of the cytoskeleton (switch from cytokeratins to vimentin) and synthesis of ECM proteins and matrix metalloproteases (24, 25, 41) . Here we correlated some of these features with vemurafenib resistance.
Switching to a mesenchymal phenotype increases the ability of a tumor to detach from the epithelial layer and migrate. Enhanced production of ECM proteins and ECM-degrading proteins promotes a more compatible microenvironment and facilitates migration of tumor cells through the host tissue (7).
Formation of macro-metastases in distant organs is associated with a reversion to an epithelial phenotype (i.e. MET) (25) . This reversion was observed at the highest level of induced vemurafenib resistance, as indicated by the cell adhesion assay and reactivation of Ecadherin. It is possible that different molecular mechanisms are involved, depending on the drug concentration used to induce resistance. At lower concentrations cells might still be able to adapt, while selection of survivors may occur at higher concentrations.
Inflammation has been associated with EMT, especially by COX-2, which induces the expression of Snail1, promoting resistance to anoikis via RAS-MAPK/ERK and PI3K activation (42) (43) (44) (45) . There was a switch in the profile of inflammatory proteins in M24met, from a normal fibroblast phenotype to a pattern associated with tumor-associated fibroblasts. and were found to be regulated by M8. As they can be monitored in blood, they may potentially provide markers for the switch to a resistant phenotype and an indicator for sensitivity to M8.
Thus, applying proteome profiling provides additional insight into mechanisms of tumorigenesis, paving the way for the identification of early biomarkers, development of new drug combinations and individualized patient stratification for optimal therapy using predictive and pharmacodynamic biomarkers. We present 7 characteristics which are associated with vemurafenib resistance and might reflect the mode of action of the drug: (1) lysosomal expression, phagosomes and glycospingolipid process; (2) metastasis, cell migration and glycosaminoglycan degradation; (3) cell adhesion and Ca2+ ion binding capability; (4) MAPK pathway; (5) enhanced expression of ECM proteins, (6) EMT and (7) enhanced transformation. We also identify 7 mechanistic strategies that might help to overcome vemurafenib resistance, namely interfering in (1) cell differentiation; (2) cell proliferation; (3) DNA damage/repair; (4) cell cycle; (5) p53 pathway; (6) redox homeostasis, and (7) mitochondrial processes.
We plan to extend these results by evaluating additional sensitive and resistant melanoma cells and melanoma tissue.The proteome analysis will be performed in 3 steps: 1. Thermo QEXACTIVE will be used for the analysis of cell fractions of Vemurafenib sensitive and resistant cells. Data will be analzed by MaxQuant. 2. PCT SWATH is used for melanoma tissue and offers an optimized protein lysis and extraction by the pressure cycling technology (PCT). Data analysis will be perfomed by OpenSWATH. 3. To evaluate the predictive power of markers in blood, selected reaction monitoring (SRM) is the method of choice. Bioinformatic analysis will be performed by mProphet.
This may offer additional understanding of the underlying mechanisms and new insights for rational therapeutic concepts preventing lethal drug resistance. 
